177Lu Radiolabeled Monoclonal Antibody HuJ591-GS (177Lu-J591) in Patients With Nonprostate Metastatic Solid Tumors: A Pilot Study
Phase of Trial: Phase II
Latest Information Update: 02 Feb 2017
At a glance
- Drugs ATL 101 Telix Pharmaceuticals (Primary)
- Indications Advanced breast cancer; Colorectal cancer; Glioma; Head and neck cancer; Non-small cell lung cancer; Oesophageal cancer; Ovarian cancer; Pancreatic cancer; Renal cancer; Solid tumours; Urogenital cancer
- Focus Therapeutic Use
- 20 Jan 2017 Planned End Date changed from 1 Dec 2017 to 1 Dec 2018.
- 20 Jan 2017 Planned primary completion date changed from 1 Dec 2016 to 1 Dec 2017.
- 04 May 2015 Planned End Date changed from 1 Jul 2012 to 1 Dec 2017 as reported by ClinicalTrials.gov record.